KLAVA Innovation

KLAVA Innovation is a French biotechnology company focused on the discovery and development of small molecule drugs targeting "undruggable" proteins in oncology. Spun off from prestigious French research institutions including Gustave Roussy, INSERM, CNRS, and Institut Curie, the company leverages a proprietary platform to identify cryptic allosteric sites. This approach allows for the modulation of protein functions that are inaccessible to traditional orthosteric inhibitors. KLAVA's initial pipeline focuses on high-value targets within the RAS pathway to address significant unmet needs in solid tumor treatment. The company's technology combines advanced structural biology with innovative screening methods to unlock previously inaccessible therapeutic targets.